The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Farkas, L. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,737
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Schmoll, H., Cutsem, E. V., Stein, A., Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Nordlinger, B., van de Velde, C. J., Balmañà, J., Reguła, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,534
Cunningham, D., Atkin, W. S., Lenz, H., Lynch, H. T., Minsky, B. D., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,447
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y., Cooper, H. S., Deming, D. A., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,333
Salem, R., Lewandowski, R. J., Mulcahy, M. F., Riaz, A., Ryu, R. K., Ibrahim, S., Atassi, B., Baker, T., Gates, V. L., Miller, F. H., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.006 · Cited by 1,070
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 668
Loupakis, F., Ruzzo, A., Cremolini, C., Vincenzi, B., Salvatore, L., Santini, D., Masi, G., Stasi, I., Canestrari, E., Rulli, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605177 · Cited by 574
Richman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Lacouture, M. E., Mitchell, E. P., Piperdi, B., Pillai, M. V., Shearer, H., Iannotti, N. O., Xu, F., & Yassine, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7828 · Cited by 486
Self-citationFOxTROT Collaborative Group (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70348-0 · Cited by 472
Machine learning approaches to drug response prediction: challenges and recent progress
Adam, G. A., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe‐Kains, B., & Goldenberg, A. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0122-1 · Cited by 459
Chibaudel, B., Maindrault‐Gœbel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., Mabro, M., Artru, P., Carola, É., Flesch, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4344 · Cited by 394
Seymour, M., Brown, S., Middleton, G., Maughan, T., Richman, S. D., Gwyther, S. J., Lowe, C., Seligmann, J., Wadsley, J., Maisey, N. R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 392
Colorectal cancer: From prevention to personalized medicine
Binefa, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6786 · Cited by 399
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M. A., Chang, G. J., Chen, Y., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D. A., Garrido‐Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 433
Self-citationSolbiati, L., Ahmed, M., Cova, L., Ierace, T., Brioschi, M., & Goldberg, S. N. (2012) · Radiology · doi:10.1148/radiol.12111851 · Cited by 365
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 363
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., Palma, R. D., Orditura, M., Vita, F. D., & Ciardiello, F. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 348
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Stereotactic body radiotherapy for colorectal liver metastases
Chang, D. T., Swaminath, A., Kozak, M. M., Weintraub, J., Koong, A. C., Kim, J., Dinniwell, R. E., Brierley, J. D., Kavanagh, B. D., Dawson, L. A., et al. (2011) · Cancer · doi:10.1002/cncr.25997 · Cited by 301
Abou‐Elkacem, L., Arns, S., Brix, G., Gremse, F., Zopf, D., Kiessling, F. M., & Lederle, W. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1162 · Cited by 283
Colorectal liver metastases: Current management and future perspectives
Martin, J. L., Petrillo, A., Smyth, E. C., Shaida, N., Khwaja, S. A., Cheow, H. K., Duckworth, A., Heister, P. M., Praseedom, R., Jah, A., et al. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i10.761 · Cited by 294
Yamazaki, K., Nagase, M., Tamagawa, H., Ueda, S., Tamura, T., Murata, K., Nakajima, T. E., Baba, E., Tsuda, M., Moriwaki, T., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw206 · Cited by 270
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Larsen, A. K., Ouaret, D., Ouadrani, K. E., & Petitprez, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.012 · Cited by 271
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 259
Kummar, S., Chen, H. X., Wright, J., Holbeck, S. L., Millin, M. D., Tomaszewski, J. E., Zweibel, J., Collins, J. M., & Doroshow, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3216 · Cited by 254
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 254
Cooper, K. L., Madan, J. J., Whyte, S., Stevenson, M., & Akehurst, R. L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-404 · Cited by 246
S3-Leitlinie – Kolorektales Karzinom
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T. G., Nothacker, M., Porschen, R., Rödel, C. M., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 247
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
Gallagher, D. J., & Kemeny, N. E. (2010) · Oncology · doi:10.1159/000315730 · Cited by 241
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Abdollahi, A., & Folkman, J. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2009.12.001 · Cited by 236
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J. E., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 230
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
B, J. R. V. B., Nowak-Sliwinska, P. M., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211
Karagkounis, G., Torbenson, M. S., Daniel, H. D. J., Azad, N. S., Diaz, L. A., Donehower, R. C., Hirose, K., Ahuja, N., Pawlik, T. M., & Choti, M. A. (2013) · Cancer · doi:10.1002/cncr.28347 · Cited by 195
Berlin, J. D., Bendell, J. C., Hart, L. L., Firdaus, I., Gore, I., Hermann, R. C., Mulcahy, M. F., Zalupski, M. M., Mackey, H. M., Yauch, R. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1800 · Cited by 182
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
Pai, R. K., Jayachandran, P., Koong, A. C., Chang, D. T., Kwok, S., Ma, L., Arber, D. A., Balise, R. R., Tubbs, R. R., Shadrach, B. L., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824430d7 · Cited by 182
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 178
Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 178
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177
Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 174
Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
Bellone, M., & Calcinotto, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00231 · Cited by 167
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
van Rhee, F., Stone, K., Szmania, S. M., Barlogie, B., & Singh, Z. N. (2010) · PubMed · Cited by 164
Cascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H. N., Nilsson, M. B., Oborn, C. J., Park, Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 166
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 162
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 166
Passardi, A., Nanni, O., Tassinari, D., Turci, D., Cavanna, L., Fontana, A., Ruscelli, S., Mucciarini, C., Lorusso, V., Ragazzini, A., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv130 · Cited by 158
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor
Hsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 148
Argiris, A. E., Kotsakis, A. P., HOANG, T. N., Worden, F. P., Savvides, P. S., Gibson, M. K., Gyanchandani, R., Blumenschein, G. R., Chen, H. X., Grandis, J. R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds245 · Cited by 148
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Siddiqui, A. D., & Piperdi, B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0811-z · Cited by 148
Evaluating Many Treatments and Biomarkers in Oncology: A New Design
Kaplan, R. S., Maughan, T., Crook, A. M., Fisher, D. J., Wilson, R. H., Brown, L. C., & Parmar, M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7905 · Cited by 141
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 142
Petrelli, F., Cabiddu, M., Borgonovo, K., & Barni, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr592 · Cited by 140
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 139
Takemura, N., Saiura, A., Koga, R., Arita, J., Yoshioka, R., Ono, Y., Hiki, N., Sano, T., Yamamoto, J., Kokudo, N., et al. (2012) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-012-0959-z · Cited by 132
Effects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
Chu, E. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.05.005 · Cited by 132
A Systems Approach for Tumor Pharmacokinetics
Thurber, G. M., & Weissleder, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024696 · Cited by 132
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Capdevila, J., Élez, E., Macarulla, T. M., Ramos, F. J., Ruiz-Echarri, M., & Tabernero, J. M. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.02.001 · Cited by 131
Meyerhardt, J. A., Li, L., Sanoff, H. K., Carpenter, W. R., & Schrag, D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9650 · Cited by 129
Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J. R., Couture, F., Moore, M. J., Price, T. J., Siddiqui, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.0543 · Cited by 126
Péron, J., Maillet, D., Gan, H. K., Chen, E. X., & You, B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3981 · Cited by 132
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 125
EGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 130
Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
Arjaans, M., Munnink, T. H. O., Oosting, S. F., van Scheltinga, A. G. T. T., Gietema, J. A., Garbacik, E. T., Timmer‐Bosscha, H., Hooge, M. N. L., Schroder, C. P., & de Vries, E. G. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3518 · Cited by 124
Tournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 126
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Chemotherapy Before Liver Resection of Colorectal Metastases
Lehmann, K., Rickenbacher, A., Weber, A., Pestalozzi, B. C., & Clavien, P. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182356236 · Cited by 120
Wasan, H. S., Meade, A. M., Adams, R., Wilson, R. H., Pugh, C., Fisher, D. J., Sydes, B., Madi, A., Sizer, B., Lowdell, C. P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70106-8 · Cited by 121
Anti-angiogenic therapies for metastatic colorectal cancer
Wagner, D., Arnold, D., Grothey, A. A., Haerting, J., & Unverzagt, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005392.pub3 · Cited by 119
Pak, L. M., Kemeny, N. E., Capanu, M., Chou, J. F., Boucher, T. M., Cercek, A., Balachandran, V. P., Kingham, T. P., Allen, P. J., DeMatteo, R. P., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24898 · Cited by 120
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N. C., Price, T. J., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 122
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside
Arjaans, M., Schroder, C. P., Oosting, S. F., Dafni, U. G., Kleibeuker, J. E., & de Vries, E. G. E. (2016) · Oncotarget · doi:10.18632/oncotarget.6918 · Cited by 116
Treatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 115
Rovers, K. P. B., Bakkers, C., Simkens, G. A. A. M., Burger, J. W. A., Nienhuijs, S. W., Creemers, G., Thijs, A. M. J., Brandt‐Kerkhof, A. R. M., Madsen, E. V. E., Ayez, N., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5545-0 · Cited by 111
Saridaki, Z., Papadatos-Pastos, D., Tzardi, M. N., Mavroudis, D., Bairaktari, E. T., Arvanity, H., Stathopoulos, E. N., Georgoulias, V., & Souglakos, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605694 · Cited by 112
Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
Finding the tumor copycat: Therapy fails, patients don’t
Ellis, L. M., & Fidler, I. J. (2010) · Nature Medicine · doi:10.1038/nm0910-974 · Cited by 109
Oikonomou, E., Koustas, E., Goulielmaki, M., & Pintzas, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2555 · Cited by 113
Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer
Fakih, M., & Vincent, M. D. (2010) · Current Oncology · doi:10.3747/co.v17is1.615 · Cited by 152
Targeting Multiple Kinase Pathways: A Change In Paradigm
Gossage, L., & Eisen, T. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3182 · Cited by 112
Vale, C. L., Tierney, J. F., Fisher, D. J., Adams, R., Kaplan, R. S., Maughan, T., Parmar, M., & Meade, A. M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.002 · Cited by 107
Amit, O., Mannino, F., Stone, A., Bushnell, W., Denne, J. S., Helterbrand, J. D., & Burger, H.-U. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.013 · Cited by 107
Sorafenib: Where Do We Go from Here?
Siegel, A. B., Olsen, S. K., Magun, A. M., & Brown, R. S. (2010) · Hepatology · doi:10.1002/hep.23633 · Cited by 106
Making the best of PARP inhibitors in ovarian cancer
Banerjee, S. N., Kaye, S. B., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.116 · Cited by 107
Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 110
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 165
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 110
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
